Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ute von Wangenheim

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Mathematical Biology|April 9, 2013
Single-crossover recombination and ancestral recombination treesEllen Baake, Ute von Wangenheim
Journal of Mathematical Biology|July 29, 2009
Single-crossover recombination in discrete timeUte von Wangenheim, Ellen Baake, Michael Baake
European Journal of Drug Metabolism and Pharmacokinetics|March 4, 2018
Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy SubjectsDoreen Luedtke, Kristell Marzin, Arvid Jungnik, et al.
Plos One|October 17, 2023
Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLCVirginie Westeel, Wolfgang Schuette, Thierry Urban, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
Clinical Lung Cancer|July 11, 2017
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural MesotheliomaGiorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)Martin Forster, Allan Hackshaw, Tommaso De Pas, et al.
Leukemia|May 16, 2019
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemiaStephan Stilgenbauer, Thérèse Aurran Schleinitz, Barbara Eichhorst, et al.
Investigational New Drugs|June 1, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Investigational New Drugs|June 25, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Mathematical Biology|April 9, 2013
Single-crossover recombination and ancestral recombination treesEllen Baake, Ute von Wangenheim
Journal of Mathematical Biology|July 29, 2009
Single-crossover recombination in discrete timeUte von Wangenheim, Ellen Baake, Michael Baake
European Journal of Drug Metabolism and Pharmacokinetics|March 4, 2018
Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy SubjectsDoreen Luedtke, Kristell Marzin, Arvid Jungnik, et al.
Plos One|October 17, 2023
Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLCVirginie Westeel, Wolfgang Schuette, Thierry Urban, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
Clinical Lung Cancer|July 11, 2017
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural MesotheliomaGiorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)Martin Forster, Allan Hackshaw, Tommaso De Pas, et al.
Leukemia|May 16, 2019
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemiaStephan Stilgenbauer, Thérèse Aurran Schleinitz, Barbara Eichhorst, et al.
Investigational New Drugs|June 1, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Investigational New Drugs|June 25, 2020
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Pageof 2